Citations 3
Omitting Bone Marrow Sampling in FDG-Avid Rhabdomyosarcoma With 2-[ 18 F]FDG PET-Negative Marrow: Results From an International Retrospective Study
Just, Marissa, Collins, Natalie B. , Crane, Jacquelyn, Harrison, Douglas, Affinita, Maria C., Allen-Rhoades, Wendy, Alessi, Alessandra , Asaftei, Sebastian Dorin , Freitag, Martin T. , Iftner, Jessica L., Khalatbari, Hedieh, Luettichau, Irene von , Mauz‐Körholz, Christine , Rovera, Guido , Sims, Justin, Voss, Stephan D. , Birz, Suzi , Sparber‐Sauer, Monika , Linardic, Corinne M. , Network, for the INSTRuCT Imaging/Pathology/Biology, Baldari, Giorgio , Borrego-Dorado, I., Baffa, Nicodemo, Caldarella, Carmelo , Degitz, Carmen , DiGianvittorio, Michael, Fischer, Alexandra, Fox, Josef J. , Fuso, Giuseppe Arturo, Hiemcke-Jiwa, Laura, Heinzel, Alexander , Jacob, Sebastian, Kleinwechter, Martha, Kröning, Pia, Lohrmann, Christian, Morani, Ajaykumar C. , Nadel, Helen, Parisi, Marguerite T. , Perruccio, Katia , Pugliano, Martina, Font, C. Ramos , Cuomo, Maria Rosaria, Saab, Raya, Schäfer, Jürgen, Schachtrup, Kristina, Sternberg, Michele, Uhl, Markus, Verberne, Hein J., Nadel, Helen , Saab, Raya , Mercolini, Federico , Shulkin, Barry L , Collins, Natalie B , Alessi, Alessandra , Asaftei, Sebastian D , Arnold, Michael A , Chen, Sonja , FitzGerald, Forrest , Freitag, Martin T , de Keizer, Bart , Mauz-Koerholz, Christine , Rossig, Claudia , Rovera, Guido , Rutkowski, Stefan , Voss, Stephan D , Birz, Suzi , Bisogno, Gianni , Ebinger, Martin , Merks, Johannes H M , Sparber-Sauer, Monika , Haller, Bernhard , Weiss, Aaron R , Linardic, Corinne M , Schoot, Reineke A , Hettmer, Simone , Nadel, Helen , Just, Marissa A. , Shulkin, Barry L. , Affinita, Maria Carmen , Allen‐Rhoades, Wendy , Chen, Sonja , Chiaravalli, Stefano , Khalatbari, Hedieh K. , Keizer, Bart de , Yoshimi, Ayami , Bisogno, Gianni , Ebinger, Martin , Weiss, Aaron R. , Cheesman, Edmund , DiGianvittorio, Michael, Fanti, Stefano , Hiemcke‐Jiwa, Laura S. , Ruffini, Livia , Scarlattei, Maura , Verberne, Hein J. , Zucchetta, Pietro
Journal of Clinical Oncology | August 24, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available
PURPOSE Detection of bone marrow disease has been a major component of rhabdomyosarcoma (RMS) staging with bilateral bone marrow aspirates/biopsies (BMAB) from the iliac crests considered the diagnostic gold standard. This study's goal was to determine if 2- 18 F-labeled fluorodeoxyglucose positron emission tomography/computed tomography ([ 18 F]FDG PET/CT) or PET/magnetic resonance imaging (MRI) may replace BMAB in RMS staging. METHODS Patients were recruited in Europe and North America. Medical records, FDG PET/CT or FDG PET/MRI (PET), and BMAB reports were collected retrospectively. Images were re-reviewed by nuclear medicine physicians at the patients' home institutions if PET reports indicated increased FDG uptake at bone/bone marrow sites or if tumor cells were detected in bone marrow samples. RESULTS PET imaging and BMAB were performed before chemotherapy and tumor resection in 301 patients with FDG-avid RMS. Bone marrow metastases were detected by PET and BMAB in 54, by PET only in 24, and by BMAB only in one of 301 patients with FDG-avid primary tumors. Absence of bone marrow metastases was confirmed by PET and BMAB in 222 of 301 patients. These observations translated into 98% sensitivity and 90% specificity for PET in detecting bone marrow metastases when BMAB was considered as gold standard. FDG-avid marrow disease was patchy (1-5 foci) in one third of cases. Patients with marrow disease indicated by PET and BMAB had more FDG-avid bone marrow foci, more metastatic sites, and lower survival than those with marrow disease indicated by PET only, suggesting more advanced disease stages. CONCLUSION Bone marrow sampling may be omitted in patients without evidence of FDG-avid bone marrow disease by PET. If there are FDG-avid bone marrow lesions, further investigation by MRI and/or biopsy should be considered.
Lymph node staging and treatment in pediatric patients with soft tissue sarcomas: A consensus opinion from the Children’s Oncology Group, European paediatric Soft tissue sarcoma Study Group, and the Cooperative Weichteilsarkom Studiengruppe
Scheltinga, Scheila E. J. Terwisscha van, Keizer, Bart de , McCarville, M. Beth , Casey, Dana L. , Walterhouse, David , Hiemcke‐Jiwa, Laura S. , Franzius, Christiane, Vokuhl, Christian , Birz, Suzi , Rodeberg, David A. , Casey, Dana L , de Keizer, Bart , Schoot, Reineke A , Routh, Jonathan C. , Seitz, Guido , Kao, Simon C. , Shulkin, Barry L. , Ewijk, Roelof van , Allen‐Rhoades, Wendy , Mercolini, Federico , Merks, Johannes H M , Orbach, Daniel , Kapadia, Tejas , Fajardo, Raquel Dávila , Corti, Federica De , Tang, Vivian , Metts, Jonathan L. , Oberoi, Saphna , Dasgupta, Roshni
No container title available | August 23, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available
10.22541/au.172445880.02878798/v1
Accurate staging of nodal involvement in pediatric sarcoma patients is important to determine correct systemic and local therapy, with the goal to reduce subsequent recurrences. However, differences in lymph node staging strategies, definitions, and treatment protocols between the Children’s Oncology Group (COG), European Pediatric Soft Tissue Sarcoma Study Group (EpSSG), and the Cooperative Weichteil Sarkom Studiengruppe (CWS), complicate comparisons. In this article we try to establish internationally recognized recommendations for lymph node assessment and treatment of children and adolescents diagnosed with RMS and NRSTS according to the Consensus Conference Standard Operating Procedure methodology.
Localized vaginal/uterine rhabdomyosarcoma—results of a pooled analysis from four international cooperative groups
Minard‐Colin, Véronique , Walterhouse, David , Bisogno, Gianni , Martelli, Hélène , Anderson, James R. , Rodeberg, David A. , Ferrari, Andrea , Jenney, Meriel , Wolden, Suzanne L. , Salvo, Gian Luca De , Arndt, Carola, Gallego, Soledad , Schwob, Dominique, Haie‐Méder, Christine, Bergeron, Christophe , Stevens, Michaël C.G. , Oberlin, Odile, Hawkins, Douglas S. , Wolden, Suzanne , Hawkins, Douglas S , Bisogno, Gianni , Merks, Johannes H M
Pediatric Blood & Cancer | May 21, 2018 | Volume: 65 | Issue: 9 | Pages: No page available
AbstractBackgroundVaginal/uterine rhabdomyosarcoma (VU RMS) is one of the most favorable RMS sites. To determine the optimal therapy, the experience of four cooperative groups (Children's Oncology Group [COG], International Society of Pediatric Oncology (SIOP) Malignant Mesenchymal Tumor Group [MMT], Italian Cooperative Soft Tissue Sarcoma Group [ICG], and European pediatric Soft tissue sarcoma Study Group [EpSSG]) was analyzed.ProcedureFrom 1981 to 2009, 237 patients were identified. Median age (years) at diagnosis differed by tumor location; it was 1.9 for vagina (n = 160), 2.7 for uterus corpus (n = 26), and 13.5 for uterus cervix (n = 51). Twenty‐eight percent of patients received radiation therapy (RT) as part of primary therapy (23% COG, 27% MMT, 46% ICG, and 42% EpSSG), with significant differences in the use of brachytherapy between the cooperative groups (23% COG, 76% MMT, 64% ICG, and 88% EpSSG).ResultsTen‐year event‐free (EFS) and overall survival (OS) were 74% (95% CI, 67–79%) and 92% (95% CI, 88–96%), respectively. In univariate analysis, OS was inferior for patients with uterine RMS and for those with regional lymph node involvement. Although EFS was slightly lower in patients without initial RT (71% without RT vs. 81% with RT; P = 0.08), there was no difference in OS (94% without RT vs. 89% with RT; P = 0.18). Local control using brachytherapy was excellent (93%). Fifty‐one (51.5%) of the 99 survivors with known primary therapy and treatment for relapse were cured with chemotherapy with or without conservative surgery.ConclusionsAbout half of all patients with VU RMS can be cured without systematic RT or radical surgery. When RT is indicated, modalities that limit sequelae should be considered, such as brachytherapy.